Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase NA 1Phase EARLY_PHASE1 1

Status

Unknown 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Plasma cell 2Breast 2Sarcoma 1Myeloid 1Head & Neck 1Genitourinary 1CNS 1

Conditions

Lymphoma 725Lymphoma, Non-Hodgkin 659Precursor Cell Lymphoblastic Leukemia-Lymphoma 585Leukemia, Lymphocytic, Chronic, B-Cell 555Lymphoma, Large B-Cell, Diffuse 440Lymphoma, Follicular 419Lymphoma, Mantle-Cell 345Burkitt Lymphoma 306Leukemia 304Leukemia, Myeloid, Acute 298Hodgkin Disease 294Lymphoma, B-Cell 281Lymphoma, B-Cell, Marginal Zone 267Recurrence 246Multiple Myeloma 205Neoplasms 200Myelodysplastic Syndromes 171Lymphoma, T-Cell, Cutaneous 171Lymphoma, Large-Cell, Immunoblastic 160Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 159Waldenstrom Macroglobulinemia 146Lymphoma, Large-Cell, Anaplastic 142Mycosis Fungoides 132Sezary Syndrome 119Immunoblastic Lymphadenopathy 108Blast Crisis 92Hematologic Neoplasms 91Lymphoma, T-Cell, Peripheral 86Leukemia, Myelogenous, Chronic, BCR-ABL Positive 86Lymphoma, T-Cell 82

Interventions

temsirolimus 1siltuximab 1Valproic Acid 1Sirolimus 1Immunoglobulin G 1Disulfides 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Castleman Disease × Lymphoid × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

NCT00412321 2014-07-01

A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease

Centocor, Inc.

Phase 1 Completed
67 enrolled
LymphoidPlasma cell

Castleman Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT00891280 2011-06-15

Dose-escalation Study of Oral CX-4945

Cylene Pharmaceuticals

Phase 1 Unknown
55 enrolled
BreastLymphoidPlasma cell

Breast Neoplasms, Castleman Disease, Multiple Myeloma, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡